Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Proceedings of the National Academy of Sciences of the United States of America
|
October 7, 2015
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma
John E Janik, John C Morris, Deirdre O'Mahony, et al.
The Journal of Clinical Investigation
|
July 8, 2025
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
Yoo Sun Kim, Barzin Y Nabet, Briana N Cortez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Melissa L Abel, Nobuyuki Takahashi, Cody Peer, et al.
Cancer Discovery
|
January 30, 2023
Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Lőrinc Sándor Pongor, Christopher W Schultz, Lorenzo Rinaldi, et al.
JAMA Oncology
|
October 12, 2023
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial
Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, et al.
Cancer Cell
|
April 13, 2021
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Anish Thomas, Nobuyuki Takahashi, Vinodh N Rajapakse, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Proceedings of the National Academy of Sciences of the United States of America
|
October 7, 2015
90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma
John E Janik, John C Morris, Deirdre O'Mahony, et al.
The Journal of Clinical Investigation
|
July 8, 2025
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
Yoo Sun Kim, Barzin Y Nabet, Briana N Cortez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2023
Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial
Melissa L Abel, Nobuyuki Takahashi, Cody Peer, et al.
Cancer Discovery
|
January 30, 2023
Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and Is Associated with Worse Outcomes
Lőrinc Sándor Pongor, Christopher W Schultz, Lorenzo Rinaldi, et al.
JAMA Oncology
|
October 12, 2023
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial
Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, et al.
Cancer Cell
|
April 13, 2021
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Anish Thomas, Nobuyuki Takahashi, Vinodh N Rajapakse, et al.
Page
of 9